Larimar Therapeutics, Inc. 8-K Filing
Ticker: LRMR · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Larimar Therapeutics, Inc. (ticker: LRMR) to the SEC on Nov 10, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market).
How long is this filing?
Larimar Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 462 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-11-10 07:01:20
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
Filing Documents
- lrmr-20251110.htm (8-K) — 44KB
- lrmr-ex99_1.htm (EX-99.1) — 55KB
- lrmr-ex99_1s1.jpg (GRAPHIC) — 184KB
- lrmr-ex99_1s2.jpg (GRAPHIC) — 739KB
- lrmr-ex99_1s3.jpg (GRAPHIC) — 570KB
- lrmr-ex99_1s4.jpg (GRAPHIC) — 431KB
- lrmr-ex99_1s5.jpg (GRAPHIC) — 324KB
- lrmr-ex99_1s6.jpg (GRAPHIC) — 348KB
- lrmr-ex99_1s7.jpg (GRAPHIC) — 142KB
- lrmr-ex99_1s8.jpg (GRAPHIC) — 439KB
- lrmr-ex99_1s9.jpg (GRAPHIC) — 287KB
- lrmr-ex99_1s10.jpg (GRAPHIC) — 278KB
- lrmr-ex99_1s11.jpg (GRAPHIC) — 335KB
- lrmr-ex99_1s12.jpg (GRAPHIC) — 317KB
- lrmr-ex99_1s13.jpg (GRAPHIC) — 391KB
- lrmr-ex99_1s14.jpg (GRAPHIC) — 369KB
- lrmr-ex99_1s15.jpg (GRAPHIC) — 463KB
- lrmr-ex99_1s16.jpg (GRAPHIC) — 136KB
- lrmr-ex99_1s17.jpg (GRAPHIC) — 456KB
- lrmr-ex99_1s18.jpg (GRAPHIC) — 234KB
- lrmr-ex99_1s19.jpg (GRAPHIC) — 261KB
- lrmr-ex99_1s20.jpg (GRAPHIC) — 367KB
- lrmr-ex99_1s21.jpg (GRAPHIC) — 265KB
- lrmr-ex99_1s22.jpg (GRAPHIC) — 176KB
- lrmr-ex99_1s23.jpg (GRAPHIC) — 403KB
- lrmr-ex99_1s24.jpg (GRAPHIC) — 145KB
- lrmr-ex99_1s25.jpg (GRAPHIC) — 396KB
- lrmr-ex99_1s26.jpg (GRAPHIC) — 312KB
- lrmr-ex99_1s27.jpg (GRAPHIC) — 278KB
- lrmr-ex99_1s28.jpg (GRAPHIC) — 389KB
- lrmr-ex99_1s29.jpg (GRAPHIC) — 339KB
- lrmr-ex99_1s30.jpg (GRAPHIC) — 318KB
- lrmr-ex99_1s31.jpg (GRAPHIC) — 130KB
- lrmr-ex99_1s32.jpg (GRAPHIC) — 349KB
- lrmr-ex99_1s33.jpg (GRAPHIC) — 393KB
- lrmr-ex99_1s34.jpg (GRAPHIC) — 310KB
- lrmr-ex99_1s35.jpg (GRAPHIC) — 315KB
- lrmr-ex99_1s36.jpg (GRAPHIC) — 318KB
- lrmr-ex99_1s37.jpg (GRAPHIC) — 219KB
- lrmr-ex99_1s38.jpg (GRAPHIC) — 136KB
- lrmr-ex99_1s39.jpg (GRAPHIC) — 431KB
- lrmr-ex99_1s40.jpg (GRAPHIC) — 338KB
- lrmr-ex99_1s41.jpg (GRAPHIC) — 390KB
- lrmr-ex99_1s42.jpg (GRAPHIC) — 407KB
- lrmr-ex99_1s43.jpg (GRAPHIC) — 178KB
- lrmr-ex99_1s44.jpg (GRAPHIC) — 464KB
- lrmr-ex99_1s45.jpg (GRAPHIC) — 383KB
- lrmr-ex99_1s46.jpg (GRAPHIC) — 466KB
- lrmr-ex99_1s47.jpg (GRAPHIC) — 136KB
- lrmr-ex99_1s48.jpg (GRAPHIC) — 376KB
- lrmr-ex99_1s49.jpg (GRAPHIC) — 133KB
- lrmr-ex99_1s50.jpg (GRAPHIC) — 360KB
- lrmr-ex99_1s51.jpg (GRAPHIC) — 123KB
- lrmr-ex99_1s52.jpg (GRAPHIC) — 330KB
- 0001193125-25-273217.txt ( ) — 23322KB
- lrmr-20251110.xsd (EX-101.SCH) — 23KB
- lrmr-20251110_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 10, 2025, Larimar Therapeutics, Inc. (the "Company") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Larimar Therapeutics, Inc. Corporate Presentation, dated November 10, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: November 10, 2025 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer